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Cellular senescence is an essential tumor suppressive mechanism that prevents the 
propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of 
tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert 
antitumor activity. However, an increasing body of evidence from preclinical studies 
demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both 
in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, 
metastasis, and resistance to therapy, in part, through expression of the senescence-associated 
secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and 
chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve 
as an important target in the fight against cancer. This commentary provides a summary of the 
discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer 
(August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of 
senescence research, heterogeneity of therapy-induced senescence, current status of 
senotherapeutics and molecular biomarkers, a concept of "one-two punch" cancer therapy 
(consisting of therapeutics to induce tumor cell senescence followed by selective clearance of 
SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key 
knowledge gaps and outlines future directions in this emerging field to improve treatment 




Cells become senescent after extensive replication that causes telomere shortening [1] or 
from exposure to genotoxic, oncogenic, and/or oxidative stress [2]. Senescent cells (SnCs) 
induced by different stimuli share some common characteristics including an essentially stable 
growth arrest, relative resistance to apoptosis, persistent DNA damage signaling, changes in 
heterochromatin, decreased lamin-B1 levels, and increased expression of the cyclin-dependent 
kinase (CDK) inhibitors, p16INK4a (p16, encoded by the INK4a/ARF locus, also known as 
Cdkn2a), p21Cip1/Waf1 (p21, encoded by Cdkn1a) [3] and senescence-associated -galactosidase 
(SA--gal) [4]. SnCs secrete a plethora of factors, including proinflammatory cytokines, 
chemokines, matrix metalloproteinases (MMPs), bioactive lipids, non-coding nucleotides 
(miRNAs, mitochondrial DNA), vesicles, and growth factors, collectively termed the 
senescence-associated secretory phenotype (SASP) [5-10]. SnCs can exist in a continuum of 
states and contribute to a variety of physiological and pathophysiological processes, including 
organogenesis and wound healing [11]. Cellular senescence is also a critical barrier for 
tumorigenesis, preventing division of cells with oncogene activation and genetic instability and 
promoting immune clearance of these cells, in part, through the SASP [12]. 
Senescence occurs after treatment with radiation and/or certain chemotherapies, known as 
therapy-induced senescence (TIS) [13, 14], through induction of DNA double strand breaks 
(DSBs) [15]. On one hand, senescence can contribute to antitumor effects and treatment 
outcomes [16]; on the other, chronic accumulation of SnCs can stimulate relapse and metastasis 
[17]. Both these effects have been linked to the SASP and clearly suggest the importance of 
cellular and tissue context. For example, some tumor cells may escape TIS with the acquisition 
of genomic changes that confer treatment resistance [18], especially under a p53-deficient 
environment and p21-driven genomic instability [19]. Also, malignant cells reprogrammed by 
 
 6 
TIS to acquire a change in lineage and/or stemness can become self-renewing tumor-initiating 
cells that cause tumor relapse and promote aggressive growth [20-22]. Studies demonstrated that 
transplanting relatively small numbers of senescent cells into young mice was sufficient to cause 
persistent physical dysfunction and spread cellular senescence to host tissues [23]. Through the 
SASP, SnCs can contribute to treatment-induced side effects such as myelosuppression, fatigue, 
and cardiovascular dysfunction [24]. Thus, for cancer treatment, inhibiting the induction of 
senescence is detrimental while promoting post-treatment SnC clearance is beneficial, timing 
being critical. Therefore, targeting SnCs, with senotherapeutics, including senomorphics (small 
molecules that partly suppress senescence phenotypes such as the SASP without cell-killing) and 
senolytics (small molecules that induce SnCs death) is an emerging strategy for cancer treatment 
[25, 26].  
Understanding the molecular pathways that regulate senescence in cancer can generate novel 
insights to guide the discovery of unique anticancer agents and molecular biomarkers. This 
approach may spur the development of novel "one-two punch" cancer treatments consisting of 
agents that induce tumor cell senescence followed by senolytics to selectively clear SnCs [27, 
28] in tumor and normal tissue, a strategy that has the potential to improve therapy and 
concurrently mitigate many treatment-related side-effects [24]. This commentary summarizes the 
research discussions on important knowledge gaps to exploit TIS (Figure 1A) and "one-two 
punch" cancer therapy on patient outcomes (Figure 1B and 2) at the NCI Workshop on 
Radiation, Senescence, and Cancer (August 10-11, 2020, Bethesda, MD, USA). 
 
Novel cellular, molecular, and epigenetic mechanisms of senescence 
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Whether senescence is a state of permanent growth arrest or reversible is controversial [29, 
30]. Senescence is one avenue whereby tumor cells evade the direct cytotoxic impact of therapy, 
thereby allowing for prolonged survival in a dormant state, with the potential to recover self-
renewal capacity and contribute to disease recurrence [31]. While unrepaired DSBs are a well-
recognized trigger of senescence, it can also be acquired in the absence of DNA damage 
response (DDR) or following DDR pathway activation in the absence of DNA damage [32]. 
Senescence can occur after treatment with inhibitors of CDK4/6 [33, 34], Polo and Aurora 
kinases [34, 35], histone deacetylases (HDAC), and other epigenetic modifiers [36]. 
Furthermore, cells may reenter the cell-cycle subsequent to a prolonged senescence arrest to 
produce progeny with chromosomal instability or a cancer stem cell-like phenotype [20] 
providing a survival advantage. Therefore, it is important to distinguish "irreversible senescence 
arrest" from "senescence-like arrest" [37], because the cells re-entering the cell-cycle after 
"senescence-like arrest" may contribute to treatment failure. 
While TIS is commonly associated with unrepaired DSBs, it may also be induced after 
damage to mitochondria [38-41], which in turn leads to increased production of reactive oxygen 
species (ROS) [42] and DNA damage [43]. Senescence in quiescent endothelial cells can be 
induced through two independent pathways: (i) activation of DDR and p53 and (ii) dysfunction 
of mitochondria [41, 44]. In addition, other mitochondrial and cytoplasmic metabolic pathways, 
including glycolysis and glutaminolysis, are critical mediators of DSB repair and DNA damage 
checkpoint responses that regulate senescence. The hexosamine biosynthetic pathway and 
downstream protein O-GlcNAcylation are attractive druggable targets to modulate radiation-
induced senescence [45, 46]. Therefore, studies on regulation of the mitochondrial and other 
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metabolic pathways impacting chromosomal integrity and senescence are essential for the 
development of novel mitigators of therapy-induced toxicities. 
There is now evidence for metabolic [47] and stem cell-like remodeling [20, 48] among SnCs 
and for the presence of an immunogenic switch that renders SnCs susceptible to an adaptive T-
cell attack [49]. Given this dynamic nature of the senescent state and the occasional cell-cycle re-
entry of previously SnCs, plasticity-associated functional capabilities may become particularly 
relevant to selective senescence escape and tumor re-progression. 
Abazeed and colleagues used single-cell RNAseq and fluorescence reporters representing 
distinct transcriptional cell states to model cell-state dynamics and TIS at the single cell level 
[50]. They found that phenotypic switching during chemotherapy, influenced by a range of 
possible senescence scenarios, caused the persistence of quiescent tumor programs. Some of 
these cells subsequently reverted to more proliferative states with variable time intervals across 
individual tumors, resulting in the development of treatment resistance and aggressive 
recurrence. Understanding distinct cell states and how single-cell behaviors establish phenotypic 
equilibrium in cancer populations and the role that SnCs play in this process is pivotal in 
elucidating the critical cell fate switches that may underlie treatment resistance (Workshop 
Presentations: Senescent cells as both drivers and suppressors of radiation-induced cancers, J. 
Campisi, Buck Institute, Novato, CA, and Animal models to study the role of senescence in 
diseases and cancer, Jan van Deursen, Rochester, MN). 
Nevertheless, therapeutic targeting of SnCs is a balancing act that must not affect the 
beneficial effects of senescence while targeting pathways of pro-tumorigenic and pathological 
senescence. Future studies could evaluate strategies to integrate senolytic therapies effectively 




Heterogeneity of SnCs 
Heterogeneity among SnCs is contextual, influenced by the cell type and tissue of origin, the 
nature of the insult causing senescence and the elapsed time after the insult occurs. 
Characterization of SnC heterogeneity is fundamental to understanding its role in tumorigenesis 
and developing cancer treatments, such as "one-two punch" cancer therapy [27, 28] (detailed 
below). Box 1 provides some important considerations regarding SnC heterogeneity. 
First, heterogeneity of SnCs is reflected in their ability to employ different senescent cell 
anti-apoptotic pathways (SCAPs) [51, 52]. For example, senescent endothelial cells rely on the 
anti-apoptotic protein Bcl-xL for survival and thus are sensitive to Bcl-xL inhibitors, whereas 
senescent adipocyte progenitors are more sensitive to a pan-tyrosine kinase inhibitor, Dasatinib 
[52]. 
Second, many SnCs can escape growth-arrest by a variety of mechanisms. For example, in 
TIS lymphoma cells, inactivation of the H3K9 histone methyltransferase, Suv39h1, or p53 can 
reverse their growth arrest [11, 20, 53]. Similar observations were made in senescent 
melanocytes induced by RAS/BRAF oncogenes after ectopic transfection with the lysine-specific 
demethylase-1 (LSD1) and the Jumonji C domain-containing histone demethylase, JMJD2C 
[53]. Infrequent but spontaneous escape from TIS is seen in breast, non-small cell lung, colon, 
and ovarian cancer cells after therapy [54]. Senescence-escape is often associated with high 
expression of CDC2 and polyploidy [55]. TIS cells can reprogram to acquire stemness and 
become more tumorigenic and drug-resistant after senescence escape [54]. Thus, strategies to 
induce and subsequently remove residual SnCs at the right time after treatment may improve 
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therapeutic efficacy and help mitigate treatment morbidity, thus improving patient quality-of-life 
(QOL). 
Third, the SnC transcriptome is highly heterogeneous and can exert opposite effects on 
tumorigenesis and response to therapy. The composition and quantity of individual SASP factors 
secreted by SnCs can vary among cell-types and depends on the stimuli [8, 17, 56]. The 
comprehensive "soluble SASP Atlases" (sSASP) of senescent human fibroblasts induced by 
radiation, RAS overexpression, or Atazanavir (a HIV protease inhibitor), and radiation-induced 
senescent renal epithelial cells indicated that only 17 sSASP factors are shared among many 
SnCs, while several other factors varied depending on tissue type and insults [8]. In contrast, 
mesenchymal stromal cells exposed to different stressors showed common senescent phenotypes 
characterized by four classes of SASP components among several phenotypes  extracellular 
matrix/cytoskeleton/cell junctions, metabolic processes, redox factors, and regulators of gene 
expression [57]. Specific SASP factors can modulate response to therapy. The SASP factors IL-
1α, IL-6, TGF-β, CXCL1, and CXCL2 secreted by oncogene-induced senescence (OIS) in 
human fibroblasts can reinforce senescence in an autocrine manner and also induce senescence 
in adjacent cells through a paracrine mechanism [17, 58, 59]. Interestingly, similar paracrine 
signaling is mediated by small extracellular vesicles (evSASP or extracellular vesicle SASP) 
released by human fibroblasts undergoing OIS and in MCF7 cancer cells treated with Palbociclib 
(a CDK4/6 inhibitor) [7]. 
Through secretion of SASP proinflammatory factors, senescent tumor and stromal cells can 
promote immune cell infiltration to clear SnCs from the tumor microenvironment (TME) [34]. 
Similarly, activation of p53 in hepatic stellate cells due to senescence induced by CCl4 and the 
carcinogen diethyl-nitrosamine in mice reduced fibrosis and cirrhosis, besides inhibiting liver 
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epithelial tumorigenesis due to immune clearance of SnCs [60]. Moreover, combining a CDK4/6 
inhibitor or an Aurora kinase A inhibitor with an MDM2 inhibitor resulted in induction of 
senescence, followed by SASP-induced tumor infiltration of cytotoxic T cells and immune 
clearance of the senescent tumor cells [61, 62]. Further, inducing TIS with combination of 
Trametinib (a MEK inhibitor) and Palbociclib activates an immune-modulatory SASP, which in 
the KrasG12D/+;Trp53−/− lung cancer mouse model results in tumor regression and prolonged 
survival through activation of NK cells. However, TIS in KrasG12D/+;Trp53−/− pancreas cancer 
renders immunologically "cold" tumors "hot", and the resulting cytotoxic T cell infiltration, 
when combined with immune checkpoint blockade, stimulates tumor regression and prolongs 
survival [12, 63]. Further characterization of the impact of SnC clearance with senotherapeutics 
using immunocompetent mice will help validate the ability of such anticancer agents to improve 
the efficacy of treatments without compromising anti-tumor immunity. 
Studies on the heterogeneity of SnCs provide unique opportunities to mechanistically dissect 
the "molecular web" of various pathways defined by contexts, such as specific cancer types, host 
tissues, stressors, and mechanism-based clinically relevant interventions. Despite many advances 
in the visualization, quantification, and characterization of SnCs in tissues and organs, several 
aspects of senescence biology remain unknown. Some noteworthy efforts to characterize SnCs 
include: the creation of a "tumor SnC atlas" with technologies such as single cell sequencing [64, 
65], gene ontology, and ingenuity pathway analyses [56], and establishment of spatial, temporal, 
and dynamic relationships between SnCs and tumor cells using Cytometry by Time of Flight 
(CyTOF) [66]. Single cell RNAseq data presented at the workshop demonstrated that TIS cells in 
culture and those isolated from aged mouse kidney exhibit different characteristics, and only a 
small percentage of p16+ SnCs from the kidney are primarily responsible for the production of 
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profibrotic SASP factors (Workshop Presentations: Senescent cells as both drivers and 
suppressors of radiation-induced cancers, Judith Campisi, Buck Institute, Novato, CA, and 
Animal models to study the role of senescence in diseases and cancer, Jan van Deursen, 
Rochester, MN). 
Intriguing mechanisms by which different SnCs use different SCAPs to resist apoptosis have 
to be elucidated [67]. However, at the core of SnC heterogeneity, characterization of whole-
transcriptome datasets seems to provide a fingerprint of 55 senescence-associated gene 
transcriptomes in fibroblasts [56]. Such tissue-specific characterization in a variety of cancers, 
particularly the specific SCAPs utilized by different SnCs in a TME, can lead to the discovery of 
novel targets and biomarkers. This will allow specific targeting of the SnCs that are more 
tumorigenic and immune-suppressive. 
Given the heterogeneity of SnCs, there is currently limited knowledge relating to its drivers 
and consequences, and how these processes could be harnessed to improve human health. NIH 
has recently identified five broad areas, in general, to advance senescence research: identification 
and characterization of SnCs, creation of senescent cell atlases, studies of biomarkers, model 
systems, and imaging tools [68]. Research in these cross-disciplinary areas will also stimulate 
and synergize research on TIS and its application to improve anticancer therapy. However, 
biomarkers, model systems, and imaging tools will require validation projects in which pathways 
of senescence are perturbed to induce, eliminate, and modulate senescence, and then assess the 
impact of those perturbations on health and disease [68]. Such demonstration projects could 
ideally use radiation at different doses and schedules to induce and study cellular perturbations, 





The advent of senotherapeutics over the last five years has enabled many proof-of-concept 
studies for age-related diseases [66, 67, 70, 71]. Although senomorphics, such as the mTOR 
inhibitor Rapamycin [72], JAK1/2 inhibitor Ruxolitinib [73], and BET inhibitor JQ1[74] may 
also be useful, the focus has been on senolytics. Table 1 provides a summary of senotherapeutics 
currently under various stages of development. Over the last decade, many targets for senolytics 
have been discovered, and several senolytics have been tested in preclinical models. However, 
the translation of senolytics to the clinic has been challenging for a number of reasons. These 
include but are not limited to SnCs heterogeneity across different tissues, organs, and model 
systems, the selectivity of drugs to deleterious SnCs, systemic toxicities, and development of 
drug resistance [75]. Box 2 summarizes important pitfalls, challenges, and opportunities 
underlying the development of senolytics as anticancer agents for clinical use. 
In mouse models, senolytics such as Navitoclax (ABT-263) selectively eliminate TIS cells 
and prevent or delay cancer relapse and metastasis [24, 76]. ABT-263, a Bcl-2/Bcl-xL inhibitor, 
used as an adjuvant therapy with radiation increases the survival of glioblastoma multiforme 
(GBM) tumor-bearing mice by eliminating senescent astrocytes with a tumor-promoting role 
(Workshop Presentation: Prevention of glioblastoma recurrence after radiotherapy by elimination 
of senescent astrocytes, Sandeep Burma, University of Texas Health Science Center, San 
Antonio, TX). Similarly, DNA-replication kinase CDC7 inhibitor-induced senescent liver and 
lung cancer cells with TP53 mutations can be selectively cleared by mTOR inhibitors; and the 
combination of inhibitors of CDC7 and mTOR statistically significantly reduced the tumor 
burden and increased survival in liver cancer xenograft mouse models [77]. Recently, Ruscetti et 
al. demonstrated in a pancreatic ductal adenocarcinoma model (PDAC), in which combination 
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therapy-induced senescence (MEK and CDK4/6 inhibitors targeting oncogenic signaling) 
triggers SASP-dependent vascular remodeling, facilitating chemotherapy uptake and SASP-
mediated endothelial activation, driving T-cell infiltration into the tumors and potentiating PD-1 
blockade [12]. 
Some approaches described below to reduce toxicities and increase efficacy are noteworthy. 
First, taking advantage of the high expression of SA-β-gal in SnCs, Gemcitabine, ABT-263, and 
Duocarmycin have been converted into promising prodrugs with galactose as a pro-moiety [78-
80]. Such prodrugs are preferentially activated in SnCs by conversion into the active parent drug 
by SA-β-gal resulting in targeting of SnCs. However, activated macrophages also express SA-β-
gal [81], so such agents will not likely be fully selective against SnCs. The second is to improve 
selectivity by constructing proteolysis targeting chimeras (PROTACs)  heterobifunctional 
molecules that link a ligand for a protein of interest to an E3 ligase ligand [82]. To improve the 
potency and reduce the severe thrombocytopenia induced by ABT-263, taking advantage of the 
low expression levels of E3 ligase Cereblon (CRBN) in platelets, PROTAC PZ15227, 
constructed by linking ABT-263 to a CRBN ligand pomalidomide, has shown improved efficacy 
and reduced toxicities compared to ABT-263 [82]. This approach could have broad applications 
if SnCs-specific E3 ligases could be identified [70, 82]. However, while this approach may 
protect against thrombocytopenia, it may not be effective in protecting against the neutropenia 
that can be induced by ABT-263 [83]. Third, the design of dendrimer-conjugated Bcl-2/xL 
inhibitor, AZD0466, to optimize drug-release rate has shown promise in reducing cardiovascular 
toxicities and improved therapeutic index in preclinical models, which allowed its progression to 
clinical studies [84]. However, as some senolytics are repurposed anti-cancer agents with known 
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on- and off-target toxicities, their dose- and scheduling need to be optimized for clinical 
applications.  
Different types of SnCs use different SCAPs to resist apoptosis. Therefore, different TIS 
cells may require different senolytics [67]. The continued discovery of new SCAPs, senolytic 
targets, and senolytics, and optimization of their dose regimen, is essential. However, current 
efforts involving structure-activity relationships and lead optimization are lagging in senolytic 
discovery. Several biotechnology companies are currently developing new senolytics. Many of 
these efforts do not directly focus on developing senolytics as anticancer agents. However, it 
includes the development of senolytics to target the transition between quiescence and 
senescence state, modulators of senescence signaling pathways and DNA repair enhancers, 
approaches to enhance the efficacy and reduce toxicities using PROTACs, and antibodies to 
promote immune-clearance of SnCs as well as novel discovery platforms [85]. Similarly, there 
are also opportunities to repurpose radiation-effect modulators [86-88] as senotherapeutics. Thus, 
we anticipate the development of a steady pipeline of senotherapeutics in the near future, which 
may be used in "one-two punch" cancer therapy. 
 
"One-two punch" cancer therapy 
To target TIS, a novel "one-two punch" cancer therapy approach represents an exciting area 
of research [27, 89], which is illustrated in Fig. 1B. Cancer therapies at clinical doses, while 
accomplishing tumor cell-killing (first punch), also induce senescence both in tumor and normal 
tissues [13, 54]. SnCs are normally cleared by immune surveillance [90]. Therapy-induced SnCs 
are heterogeneous and dynamic, also reflected in biomarkers, cellular plasticity, expression of 
SASPs and SCAPs, the tissue of origin, and cell-lineage [8, 13, 52]. Selective clearance of SnCs 
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with a senotherapeutic (second punch) in tumors can prevent tumor relapse, metastasis, and 
development of resistance to treatment [27, 89]. Similarly, selective clearance of SnCs in normal 
tissue in a dynamic spatiotemporal environment will prevent, treat, and mitigate therapy-induced 
side effects and help restore tissue homeostasis. However, the time of administration of the 
"second punch" therapy will be important to improve efficacy. The report on the "one-two 
punch" approach to selectively eliminate chemotherapy-induced senescent lymphoma cells in 
mice was achieved by using a metabolic senolytic to block glucose utilization or autophagy [47]. 
Genetic and pharmacological clearance of TIS cells reduces side-effects and inhibits tumor 
relapse and metastasis [24]. A combination of chemotherapy and a senolytic therapy (e.g., 
ABT263 or cardiac glycosides) is effective in the treatment of many cancer types in mouse 
models [77, 91-94]. The combined treatment with XL413 (a potent CDC7 inhibitor) and 
AZD8055 (mTOR inhibitor) resulted in pronounced growth inhibition of liver cancer [77]. 
Recently, chimeric antigen receptor T (CART) cells targeting the cell surface protein, urokinase-
type plasminogen activator receptor (which is broadly present in SnCs), was found effective as a 
senolytic in a KrasG12D;p53−/− lung adenocarcinoma mouse model demonstrating proof-of-
principle for synthetic senolytic cell-based therapy [95].  
Clearance of TIS cells can improve post-treatment QOL by mitigating cancer treatment- 
induced acute and late effects such as radiation-induced tissue fibrosis and chemotherapy-
induced neuropathy [76, 96, 97]. Interestingly, in some immunocompetent mouse tumor models, 
TIS is found to be beneficial, since it can also promote immune clearance of tumor cells through 
SASP factors along with clearance of SnCs [34, 60, 63, 98]. The underlying causes of the 
differential effects of SnCs on tumorigenesis and response to therapy have not been fully 
elucidated. For example, SnCs induced immediately after therapy and those that accumulate over 
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time may have different effects regarding antitumor immunity and tumor relapse, metastasis, and 
drug resistance [17]. In addition, the SASP itself may change over time. 
The first report on the combination of Dasatinib and Quercetin (D+Q) as an effective 
senolytic therapy in a preclinical model was discovered using a hypothesis-driven, mechanism-
based, and bioinformatics approach [67]. The results of two early phase clinical trials have now 
been published: (i) the first-in-human open-label pilot study (NCT02874989) demonstrated the 
feasibility and provided initial evidence that senolytic intervention with the above combination in 
participants with idiopathic pulmonary fibrosis can alleviate physical dysfunction [99] and (ii) 
subsequently it was demonstrated that treatment with D+Q administered to subjects with diabetic 
kidney disease statistically significantly reduces the SnCs burden (NCT02848131) [51, 100]. 
Thus, several senolytics, including D+Q [51, 67, 100], Fisetin [71], UBX0101 [101], and 
UBX1325 [102], have now progressed into clinical trials (see Table 1), and some also have 
progressed to Phase 2 studies. 
The timing of senotherapeutic administration is a key determinant of the efficacy of the "one-
two punch" strategy, because surveillance of SnCs is executed by cytokines and chemokines; 
release of which is time dependent. For example, the role for CCR2+ myeloid cells in liver 
cancer is context-specific during disease progression. While hepatocyte-secreted chemokines 
suppress liver cancer initiation, they may also promote and accelerate the growth of fully 
established liver cancers [103]. Since the effect of dose and scheduling of senolytics on the 
clearance of SnCs are not known and the range of potential beneficial or deleterious outcomes 
elicited by a "one-two punch" therapy is also not known, additional studies are necessary in a 




Promises, pitfalls, and barriers for clinical translation of senotherapy and 
"one-two punch" cancer therapy 
Increased expression of biomarkers associated with but not specific for SnCs is detected in 
numerous human cancers. For example, increased expression of p16INK4a is associated with an 
increased risk of tumor relapse and poor prognosis in breast cancer [104, 105] and the 
senescence-associated gene signature in peritumoral tissue correlates with shorter recurrence-free 
survival in hepatocellular carcinoma [11]. In contrast, in malignant pleural mesothelioma 
patients after chemotherapy, increased expression of p16INK4a is associated with better survival 
[106]. This incongruity may reflect human tumor heterogeneity in response to treatment. 
Therefore, the juxtaposed roles of SnCs in tumorigenesis and treatment response may be 
contextual; it may be dependent on tumor and tissue type of origin. In this regard, our 
understanding of SnC heterogeneity is limited by our inability to spatiotemporally and 
unambiguously detect, characterize, and monitor SnCs in patients during the course of treatment 
due to the lack of reliable SnC biomarkers and tools to detect them [68]. 
Since discovery of the first potential senescence biomarker detectable in normal human skin 
[4], it has become clear that there are no universal senescence-specific biomarkers, whether in 
normal (young or old) or malignant tissue. Hence, there has been a concerted effort to develop 
biomarker panels for identifying senescent cells in vivo [6, 68, 107, 108]. Among the recognized 
senescence biomarkers include CDK inhibitors 2A (p16/CDKN2A) and 1A (p21/CDKN1A), 
which suppress cell proliferation. However, recent tissue diagnostic array studies of cells 
expressing p16 and p21 indicated that although different organs express different levels of 
proteins as a function of age across the human life span, some tissues such as muscle do not 
appear to have either of these markers [109]. Moreover, senescence biomarkers are highly 
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variable, whether in normal or tumor tissue, and they can depend on the cell type, senescence 
inducer, and time after senescence induction [8]. Therefore, reliable SnC biomarkers to spatially 
identify and longitudinally track SnCs are urgently needed (e.g., non-invasive imaging) for 
successful translation. Of note, Dr. Jesus Gil showed preliminary data from his collaboration 
with Dr. Lars Zender at the University of Tübingen, Germany, on using PET imaging in the 
brain of a GBM patient to monitor TIS cells and their clearance by Digoxin (Workshop 
Presentation: Strategies to target senescence, Jesus Gil, Imperial College, London, UK). 
However, a major limitation to the clinical translation of senotherapeutics is the inability of 
animal models (human xenografts and/or genetically engineered models) to recapitulate fully key 
mechanisms and predict outcomes for human patients. In this regard, patient-derived xenograft 
(PDX) or spontaneous tumor models may serve to better recapitulate tumor biology and 
heterogeneity of human diseases and predict clinical outcomes [110]. Similarly, studies with 
human tumor organoids and tissue explants may also be useful [111]. 
Despite these limitations, progress has been made in monitoring and understanding systemic 
SnC burden in cancer patients and the role of SnCs in therapy-induced side effects. Increased 
expression of p16INK4a mRNA in peripheral blood T cells (PBTC, specifically CD3+ cells) can be 
used as a biomarker for measuring SnC burden and accelerated aging induced by chemotherapy 
[112, 113]. Frail patients had higher levels of PBTC p16INK4a mRNA than healthy subjects, 
suggesting that chemotherapy accelerates aging [113]. These biomarkers may be useful for 
monitoring the post-treatment QOL of patients. In this regard, an open-label intervention 
collaborative clinical trial (1U01CA246510-01; PIs: Dr. Gregory Armstrong, St. Jude Children' s 
Hospital, Memphis, TN and Dr. James Kirkland, Mayo Clinic, Rochester, MN) sponsored by the 
NCI is noteworthy 
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(https://projectreporter.nih.gov/project_info_description.cfm?aid=9890475&icde=0). This trial is 
testing whether D+Q or Fisetin alone can modify the biological markers of aging including 
PBTC p16INK4a mRNA and frailty in adult survivors of childhood cancer by the clearance of 
SnCs. 
Senolytics appear to be most effective when administered in a "hit and run" fashion. 
Following chemotherapy and/or radiotherapy, it can only take a few days to a couple of weeks 
for cells to acquire SnC phenotypes and be regarded as logical therapeutic targets. TIS in tumors 
and normal tissue, following the completion of a cancer treatment regimen, can occur between 
10 days to 6 weeks. Senolytics act quickly within 18 h eliminating the SnCs induced by therapy 
[23] and do so in a "hit and run " fashion [26, 114]. For example, in mice with age-related 
osteoporosis, treatment with D+Q, which has an elimination half-life of 4 and 11 h, respectively, 
for one day every month for 4 months, was effective in restoring bone mass [115]. This 
intermittent treatment with senolytics greatly reduced toxicities as well as those off-target effects 
caused by continuous presence of the drugs, such as those due to sustained occupancy of a 
receptor or activation or inhibition of an enzyme. Hence, senolytics could be administered 
starting from 0.5 days to 2 weeks after each round of therapy. Further, every 
chemotherapy/radiotherapy cycle could be followed by senolytics to prevent tumor recurrence 
and decrease adverse effects (Figure 2).  
Tissue-specific heterogeneity of responses of tumor and normal cells to chemotherapy has 
been demonstrated with CDK4/6 inhibitors, which induce a "transient cell-cycle block" to exert a 
protective effect in healthy cells due to Ink4 deficiency, which decreases treatment-related 
toxicities (Workshop Presentation, Keynote Address: Protecting the bone marrow from ionizing 
radiation, Norman Sharpless, NCI, Bethesda, MD) [116]. For example, selective, transient, and 
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reversible inhibition of CDK4/6 kinase activity in the bone marrow with Trilaciclib protects 
against hematopoietic stem cell (HSC) exhaustion induced by serial treatments with 5-
Fluorouracil in a murine model [117]. CDK4/6 inhibitors were also found to preserve HSC 
function in NSCLC patients treated with Etoposide and Carboplatin without reducing treatment 
efficacy [118]. Further, CDK4/6 inhibitors exhibit excellent in vivo pharmacology and 
tolerability in patients with metastatic triple negative breast cancer [119]. Trilaciclib is now 
approved to treat HR+/HER2− advanced breast cancer through induction of G1/S cell cycle arrest 
and senescence in tumor cells [120, 121]. In combination with MDM2 inhibition, preclinical 
studies show CDK4/6 inhibition combined with MDM2 inhibition is quite effective in inhibiting 
NRAS mutant melanoma tumor growth by induction of senescence, followed by immune-
mediated tumor cell clearance [61]. Studies with CDK4/6 inhibitors are examples of several 
possibilities of combining agents with differential effects and exploiting differential 
vulnerabilities in tumor and normal cells, to improve treatment efficacy in cancers and decrease 
toxicities. However, tissue-specific heterogeneity in TIS is a challenge to be overcome and an 
opportunity to improve patient outcomes. 
 
Conclusions and new directions 
Since the discovery of cellular senescence by Hayflick [122], senescence is now understood 
to be a fundamental biological process that governs a variety of pathophysiological functions and 
diseases including cancer. As the number of cancer survivors is growing due to ever improving 
treatments, focus on treatment-induced adverse effects has become even more imperative, as is 
the opportunity to study and mitigate TIS to improve further the treatment and also the QOL of 
survivors. With SnCs emerging as an anticancer target, the NCI is developing promising 
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strategies to prevent, slow, and reverse age-related consequences of cancer and its treatment 
[123]. Continuing these efforts, this workshop focused on TIS to identify key knowledge gaps in 
the discovery, development, and translation of senotherapeutics for clinical use. 
While many drugs could be used to study TIS, a simpler approach is to use radiation in 
experimental models due to its well-defined ability to induce senescence in vivo by a single total 
body dose without the confounding pharmacokinetic effects of drugs [124]. The work described 
herein demonstrates the feasibility of using established cancer treatments to induce and study 
cellular senescence, which provides the opportunity to discover novel targets, biomarkers, and 
senotherapeutics to improve efficacy and reduce toxicities of cancer therapies. Accordingly, 
studies on the many shared and pivotal molecular pathways between cancer and senescence and 
the possibility of using therapies such as radiation to induce and study defined cellular 
perturbations, including senescence, is one of many opportunities. Similarly, the promise of 
using a "one-two punch" therapy to improve treatment's efficacy and reduce SnC burden to 
improve outcomes is exciting. Figure 2 illustrates one approach to integrate "one-two punch" 
cancer therapy with adaptive tumor therapy to improve efficacy by reducing drug resistance, 
preventing tumor recurrence and injury to normal tissue, and mitigate and treat adverse effects. 
Many questions listed in Box 3 are yet to be fully understood, as discussed at the workshop. 
For example, while the data whether senescence occurs in response to chemotherapy (or 
radiation) in the clinic is relatively sparse. Also, we must understand if the induction and 
promotion of senescence are treatment specific. Further, if senescence response is uniform or 
limited to certain malignancies/drugs or radiation?  Similarly, is there a difference in the 
occurrence of senescence for each drug and malignancy? Addressing such questions is vital to 
design appropriate clinical trials and get the full benefit from the “one-two punch therapy.  
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By understanding TIS, we can anticipate a steady pipeline of novel biomarkers and 
senotherapeutics and can plan to translate senotherapeutics into next-generation anticancer 
agents. Furthermore, the identification of novel biomarkers should enable more personalized 
treatments, which is more patient/malignancy/treatment specific. Successful translation of 
senotherapeutics will ultimately involve obtaining regulatory approval from the U.S. Food and 
Drug Administration. Studies of senotherapeutics present unique regulatory challenges, 
especially when used as combined treatment modalities with chemotherapy and radiation: 
different toxicity profiles and timelines are likely for the development of adverse acute and late 
effects between systemic therapies and radiation. Cancer therapeutic-senotherapeutic drug 
combinations will also present challenges in clinical trial design. Therefore, an early interaction 
with the FDA is important if the laboratory data are compelling to consider general aspects 
related to the development and translation of senotherapeutics and obtain further guidance. 
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Table 1. Summary of senotherapeutics at various stages of developmenta. 
Drug Class Agent (Company) Mechanism of Action Developmental Stage Reference(s) 





HSP inhibitors Optimization Fuhrmann-Stroissnigg et al. 2017 
[125] 
 
Curcumin analog, EF24 Promotes degradation 
of anti-apoptotic 
Bcl-2 proteins 
Discovery Li et al. 2017 [126] 
 
Piperlongumine and analogs OXR1 and other  Discovery Liu et al. 2018 [127],  
Wang et al. 2016 [128], Zhang et 
al. 2018 [129] 
Cardiac glycosides: 




Discovery/Drug Repurposing Guerrero et al. 2019 [93], Triana-






Skeletal Health (NCT04313634) 
Frail elderly (NCT03675724) 
Osteoarthritis (NCT04210986) 
Chronic kidney disease, Diabetes mellitus, and Diabetic 
nephropathies (NCT03325322) 
Mild cognitive impairment (NCT02741804) 
COVID-19 (NCT04476953) 
Zhu et al. 2017 [71] 
Yousefzadeh et al. [130] 
Quercetinb Activates estrogen 
receptors and 
inhibits PI3 kinase 
 
Clinical trials: 
Alzheimer's disease (NCT04063124) 
Chronic kidney disease (NCT02848131) 
Hematopoietic Stem Cell Transplant (NCT02652052) 
Skeletal Health in Older Humans (NCT04313634) 
Zhu et al. 2015 [67] 
Targeted therapeutics A1155463 
(Abbvie, North Chicago, IL) 
Bcl-xL inhibitor Preclinical tool compound Zhu et al. 2017 [71] 
A1331852 
(Abbvie, North Chicago, IL) 
Bcl-xL inhibitor Preclinical tool compound Zhu et al. 2017 [71] 
Navitoclax (ABT-263) 
(Abbvie, North Chicago, IL) 
Bcl-2/Bcl-xL inhibitor Preclinical Zhu et al. 2015 [67] 




(Abbvie, North Chicago, IL) 
Bcl-2/Bcl-xL inhibitor Preclinical Yosef et al. 2016 [132] 
Dasatinibb Pan receptor tyrosine 
kinase inhibitor 
Clinical trials: 
Alzheimer's disease (NCT04063124) 
Chronic kidney disease (NCT02848131) 
Hematopoietic Stem Cell Transplant (NCT02652052) 
Skeletal Health in Older Humans (NCT04313634) 
Zhu et al. 2015 [67] 
JQ1 BET inhibitor Preclinical Tasdemir et al. 2016 [74] 
P5091 
(DFCI, Boston, MA) 
USP7 inhibitor Discovery He et al. 2020 [133] 





Preclinical Baar et al. 2017 [135] 
UBX010 
(Unity Biotechnology, 




Clinical trial terminated 
Vilgelm et al. 2019 [61] 
Vilgelm et al. 2015 [62] 
Jeon et al. 2017 [101] 
UBX-1325 
(Unity Biotechnology, 




Diabetic macular edema (NCT04537884) 






DNA alkylating agent 
 
Discovery Guerrero et al. 2020 [79] 
Gemcitabine galactose 
conjugate 
Nucleoside analog Discovery Cai et al. 2020 [80] 
PROTACs ARV825 
(Avnias Inc., New Haven, 
CT) 
BET family protein 
degrader 
Discovery Waikita et al. 2020 [136] 
PZ15227 
(University of FL, 
Gainesville, FL) 
Bcl-xL degrader Discovery 
 
He et al. 2020 [82] 
aThis is not a comprehensive list of senotherapeutics but provides some examples of classes of drugs developed as senotherapeutics.  
bUsed in combination with each other. 








Box 1. Important gaps and considerations in the understanding of the heterogeneity of 
therapy-induced senescence (TIS) 
 
 TIS is heterogeneous and context- (e.g., tissue of origin, nature of stress, and time 
after insults) dependent, and therefore, characterization in a variety of contexts is 
important for the development of novel approaches to cancer therapeutics such as 
"one-two punch" therapy. 
 Senescent cell (SnC) heterogeneity is also reflected in the use of different SnC anti-
apoptotic pathways (SCAPs) to resist cell death. 
 Many TIS-induced SnCs escape from growth arrest, which can result in the 
acquisition of plasticity, stemness, tumorigenic, and aggressive growth phenotypes. 
 SnC transcriptomes are also heterogenous, can exert contextually dichotomous 
effects on responses to therapy and tumorigenesis. 
 Specific SASP factors can modulate the responses of tumor cells and normal tissues 
to therapy, resulting in inhibition and/or promotion of tumorigenesis and induction of 
normal tissue injury. 
 The creation of a comprehensive atlas of SnCs may accelerate the discovery and 
development of novel biomarkers and senotherapeutics as next-generation anticancer 
agents to achieve better outcomes for cancer patients. 
 Time of administration of senotherapeutics may be an essential determinant in the 




Box 2. Pitfalls, challenges, and opportunities in the development of senolytics as anticancer agents for 
clinical use 
 
 Discovery. Current efforts involving structure-activity relationships and lead  
optimization are lagging in senolytic discovery. Medicinal chemistry-based research is 
needed.  
 Experimental Models. Suitable, reliable, and efficient in vitro and in vivo models for 
evaluation of the safety and efficacy of senolytics are needed. 
 Specificity. Further characterization of SnCs is necessary to allow improved targeting of 
"harmful SnCs" with sparing of immune-modulating SnCs. 
 Toxicities. Most senolytics developed from anti-cancer agent pipelines demonstrate on and 
off-target toxicities.  
o For example, Bcl-xL specific inhibitors A1155463 and A1331852 can cause severe 
thrombocytopenia because platelets depend on Bcl-xL for survival. Similarly, Bcl-
xL/Bcl-2 dual inhibitors ABT-263, ABT-737, and UBX-1325 can also cause severe 
neutropenia because neutrophils depend on Bcl-2 for survival. Improved selective 
targeting with PROTACs may reduce toxicities. 
o Senolytic prodrugs rely on SA-β-gal for SnC selective activation. However, macrophages 
also express high levels of β-gal. To reduce off-target toxicities by using prodrugs, 
however, SnCs specific activation enzymes need to be identified.  
 Time of administration. The effectiveness of senolytics may depend on the time of 
administration following cancer therapy. Senolytics are most effective when administered in a 
"hit and run" fashion reducing potential toxicities and off-target effects. 
 Drug resistance. SnCs in tumors may not be in a state of "permanent growth arrest" but can 
subsequently acquire "stemness" and/or plasticity, leading to drug resistance and metastasis. 
 Mechanisms of action. A clearer understanding of the mechanisms of action of senolytics is 
necessary, particularly for those natural product senolytics or their derivatives including, 
Quercetin, Fisetin, Piperlongumine and analogs, Curcumin analog EF-24, and cardiac 
glycosides Digoxin, Ouabain, and Proscillaridin A. 
 Intellectual property rights. Most senolytics are obtained from natural products, or derivatives 
of natural products, repurposed anticancer agents, or off-patent. Therefore, they are not 
commercially viable for pharmaceutical industries. 
 Regulatory barriers. Some senolytics are botanical products or derivatives, which need to be 
registered as investigational drugs with FDA. Because of the heterogeneity and possible 
uncertainty about active constituents, the efficacy of the drugs can vary from "batch-to-
batch." 
 Clinical studies.  
o Safety requirement for senolytics is relatively high as these drugs are intended to treat 
elderly patients or patients undergoing cancer treatments who have low tolerability to 
toxicity. Although multiple trials of senolytics have begun, it will take several years to 
complete these trials. 





Box 3. Key Knowledge Gaps in Therapy-Induced Senescence (TIS) Research for the Discovery 
and Development of Senotherapeutics as a Novel Anticancer Strategy and to Guide the 
Personalization of Cancer Treatment 
 
 Can we use radiation/chemotherapy as a model to induce and study cellular perturbations 
that cause senescence and/or cancer and improve outcomes? 
 Which is the critical type and level of biological damage (DNA mainly) shifting the 
balance towards senescence or apoptosis? 
 What are the differences between TIS in normal tissue and the tumor microenvironment? 
 Is induction and promotion of senescence treatment specific? Is the response uniform or 
heterogeneous across tumor types? Is the time frame of senescence occurrence after 
treatment dependent on treatment and tumor types? 
 Can TIS be used to unravel the intersecting mechanisms of carcinogenesis and 
senescence? 
 Will TIS be a viable approach to discover and develop novel senotherapeutics that can 
also serve as novel cancer therapies? 
 Can senotherapeutics improve the efficacy of radiation and chemotherapy without 
compromising anti-tumor immunity? 
 Is the timing of senotherapeutics following treatment important for determining the 
efficacy of "one-two punch" cancer therapeutics? 
 Are there any biomarkers that can predict or monitor the effectiveness of 
senotherapeutics? 
 Understanding the effect of TIS on the release of a heterogeneous SASP formed by 




Figure 1. Senescent cell as a target in "one-two punch" cancer therapy. A) Key knowledge 
gaps and future directions to advance "one-two punch" cancer therapy. (B) Therapy-induced 
senescence (TIS) and "one-two punch" cancer therapy. Cancer therapies (first punch) induce 
senescence both in tumor and normal tissue. SnCs are normally cleared by immune surveillance 
but can accumulate after cancer therapy. Therapy-induced SnCs are heterogeneous and dynamic, 
which is also reflected in biomarkers, cellular plasticity, expression of SASPs and SCAPs, tissue 
of origin, and cell-lineage. Selective clearance of SnCs with a serotherapeutic (second punch) in 
tumors will prevent tumor relapse, metastasis, and development of resistance to treatment. 
Similarly, selective clearance of SnCs in normal tissue in a spatiotemporal dynamic environment 
will prevent, mitigate, and treat therapy-induced side effects and restore tissue homeostasis. 
However, time of administration of the second punch therapy will be important to improve 
efficacy. The figure was created with BioRender.com. SnCs = senescent cells; SASP = 
senescence-associated secretory phenotype; SCAPs = senescent cell anti-apoptotic pathways. 
 
Figure 2. Schematic diagram of an approach to integrate "one-two punch" cancer therapy with 
personalized adaptive tumor therapy. To therapeutically exploit and benefit from the differences 
in response to treatment between tumor and normal tissue for the best patient outcome, factors 
that should be considered for pretreatment planning include tumor molecular profiling, tumor 
heterogeneity, imaging, identification of target(s), metabolic status, and planned integrated 
biomarkers for tumor diagnosis and treatment matching [137]. Similar profiling of normal tissue 
response to treatment may include determination of genetic susceptibility, immune status, 
stromal tissue subsets, the impact of the anatomical location of the tumor on normal tissue, 
metabolic status, and biomarkers that predict response and adverse effects. In a "one-two punch" 
 
 40 
therapy, punch #1 may include spatially targeted radiotherapy (e.g., dose-boost to hypoxic 
regions), molecularly targeted drugs, and/or immune therapy to the tumor, which will induce TIS 
in the tumor, stroma, and bystander tissue. Thus tumor, stroma, and bystander tissue all need to 
be evaluated for TIS for the second punch to be successful. Biomarker-driven TIS evaluation 
will be essential to optimize immune modulation, dose, and schedule of the second punch with a 
suitable senolytic. Along with dynamic adaptive tumor targeting (with drugs, immune 
modulators, and radiation), the use of different types of senolytics may be necessary to address 
spatial, temporal, and tissue heterogeneity among tumors and SnCs. Repeat treatment courses 
(punch #n) with senotherapeutics (senolytics or senomorphics) may be necessary to prevent 
tumor recurrence, drug resistance, plasticity, and normal tissue injury and mitigate and/or treat 
adverse effects months to years after completing the "one-two punch" therapy for optimal tissue 
remodeling and tissue function restoration. Dotted boxes represent current biomarkers and future 
opportunities to develop diagnostics or therapeutics for precision medicine in TIS. Tissues are 
indicated by the colors red (tumor), green (normal tissue), blue (stroma and immune related to 
tumor), and brown (bystander tissues). The figure was created with BioRender.com. Molec. = 
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